Bizarre Patents
An automatic bed maker which uses the expansion of inflatable bladder to straighten, align, and tuck-in bed-cover assembly.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120128643 | GENE VECTOR A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of t... | 05/24/2012 |
| 20120128704 | REPERTOIRE OF ALLO-RESTRICTED PEPTIDE-SPECIFIC T CELL RECEPTOR SEQUENCES AND USE THEREOF The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. Th... | 05/24/2012 |
| 20120107284 | Stem cells for transplantation and methods for production thereof A medicament for cell differentiation to alleviate cell and cell-related deficiencies in a mammal is described. The medicament comprises in two or more parts in vitro produced non-activated inducible gene construct(s) capable of expressing transcription factor(s), and o... | 05/03/2012 |
| 20120107286 | PLURIPOTENT STEM CELLS Methods and compositions for the generation and use of footprint-free human induced pluripotent stem cells are provided.... | 05/03/2012 |
| 20120107285 | Mitochondrial enhancement of cells Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, m... | 05/03/2012 |
| 20120082650 | METHODS FOR TREATING PARKINSON'S DISEASE AND OTHER DISORDERS OF DOPAMINERGIC NEURONS OF THE BRAIN A specific clinical protocol for use toward therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Parkinson's disease. The protocol is practiced by directly delivering a ... | 04/05/2012 |
| 20120070419 | METHOD OF ALTERING THE DIFFERENTIATIVE STATE OF A CELL AND COMPOSITIONS THEREOF The present invention provides a method of altering the differentiative state of cells utilizing innovative protein expression constructs encoding transcription factors. The methods and compositions described herein may be used to generate induced pluripotent stem (iPS)... | 03/22/2012 |
| 20120070430 | IDENTIFICATION OF TUMOR-ASSOCIATED MARKERS FOR DIAGNOSIS AND THERAPY The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.... | 03/22/2012 |
| 20120073002 | PREVENTION AND TREATMENT OF BLOOD COAGULATION-RELATED DISASES Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplyi... | 03/22/2012 |
| 20120039858 | METHODS AND COMPOSITIONS FOR INHIBITING PROPAGATION OF VIRUSES USING RECOMBINANT TETHERIN CONSTRUCTS The present invention provides chimeric protein constructs having anti-viral activity, compositions and methods of using them, and nucleic acids encoding them. The chimeric proteins include an extracellular domain of a Tetherin protein fused to the transmembrane domain,... | 02/16/2012 |
| 20120039859 | Method of Diminishing The Symptoms of Neurodegenerative Disease A method of diminishing the symptoms of neurodegenerative disease in a patient is disclosed. In one embodiment, the method comprises the steps of: (a) identifying a patient with a neurodegenerative disease, (b) producing a cell culture, wherein the cell culture comprise... | 02/16/2012 |
| 20120034249 | Methods for Treating Progressive Multifocal Leukoencephalopathy (PML) The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.... | 02/09/2012 |
| 20120034197 | HIV-RESISTANT STEM CELLS AND USES THEREOF Disclosed are recombinant stem cells that are resistant to HIV infection. Also disclosed are their uses in treating AIDS.... | 02/09/2012 |
| 20120027807 | TISSUE ENGINEERED MYOCARDIUM AND METHODS OF PRODUCTION AND USES THEREOF The present invention generally relates to a population of committed ventricular progenitor (CVP) cells and their use to generate a tissue engineered myocardium, in particular two dimensional tissue engineered myocardium which is comparable to functional ventricular hea... | 02/02/2012 |
| 20120027847 | CELL LINES AND THEIR USE IN ENCAPSULATED CELL BIODELIVERY The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon sy... | 02/02/2012 |
| 20120027786 | GENETICALLY PROGRAMMABLE PATHOGEN SENSE AND DESTROY Aspects of the invention relate to compositions and methods for using recombinant cells to sense and destroy specific pathogens.... | 02/02/2012 |
| 20120020940 | ANTIMICROBIAL PEPTIDES The present invention relates to a peptide comprising or consisting of the following amino acid sequence: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12 (formula II), wherein A0 is a hydrophobic amino acid residue or is absent; A1, A4, A7, A8, A12 each are a hydrophobic amin... | 01/26/2012 |
| 20120020949 | MHC-LESS cells The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.... | 01/26/2012 |
| 20120020939 | MHC-less cells The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.... | 01/26/2012 |
| 20120020987 | MHC-Less cells The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.... | 01/26/2012 |
| 20120020938 | MHC- less cells The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.... | 01/26/2012 |
| 20120021039 | EXPRESSION OF NEUROPEPTIDES IN MAMMALIAN CELLS The present application relates to expression constructs capable of securing correct processing of neuropeptides upon expression in mammalian cells, and to mammalian cells secreting correctly processed peptides. One exemplary peptide is galanin. The application also rel... | 01/26/2012 |
| 20120020885 | MHC-Less cells The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.... | 01/26/2012 |
| 20120014932 | Methods for treating disorders of amino acid metabolism The invention is directed to methods for treating disorders of amino acid metabolism, in particular, phenylketonuria (PKU). Such methods utilize novel compositions including Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) alone or in combin... | 01/19/2012 |
| 20120014879 | USE OF TUMOR NECROSIS FACTOR-alpha RECEPTOR p75 FOR TREATMENT OF ISCHEMIA-INDUCED NEOVASCULARIZATION Improvements on the basic method used for BEAMing increase sensitivity and increase the signal-to-noise ratio. The improvements have permitted the determination of intrinsic error rates of various DNA polymerases and have permitted the detection of rare and subtle mutat... | 01/19/2012 |
| 20120009160 | CELLS FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural... | 01/12/2012 |
| 20120009161 | THERAPEUTIC RETROVIRAL VECTORS FOR GENE THERAPY Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.... | 01/12/2012 |
| 20120009162 | T CELL RECEPTOR AND NUCLEIC ACID ENCODING THE RECEPTOR Disclosed are: polypeptides for TCR α-chain and β-chain which are restricted to HLA-A*0201 for Aur-A and are derived from a CTL; and nucleic acids encoding the polypeptides. The nucleic acids can impart a cytotoxic activity against a cell capable of presenting an HLA-... | 01/12/2012 |
| 20120009190 | IDENTIFICATION AND METHOD FOR USING THE PRE-LIGAND ASSEMBLY DOMAIN OF THE IL-17 RECEPTOR The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides comprising an amino acid sequence of a domain (e.g., a Fibronectin Ill-like domain) of an IL-17 Receptor (IL-17R) family member, wherein the PLAD polypeptide inhibits multimerization of a rec... | 01/12/2012 |
| 20120010499 | USE OF NANOPARTICLES FOR THE TREATMENT OF CANCER The invention relates to the tracking of mesenchymal stem cells (MSCs) labeled with magnetic nanoparticles using magnetic resonance imaging (MRI) and the use of this method for the treatment of cancer.... | 01/12/2012 |
| 20120004642 | IN VITRO MICRO-ORGANS, AND USES RELATED THERETO Micro-organ cultures which include isolated populations of cells having specific characteristics are described. Salient features of the subject micro-organ cultures include the ability to be maintained in culture for relatively long periods of time, as well as the prese... | 01/05/2012 |
| 20120003195 | IN VITRO MICRO-ORGANS, AND USES RELATED THERETO Micro-organ cultures which include isolated populations of cells having specific characteristics are described. Salient features of the subject micro-organ cultures include the ability to be maintained in culture for relatively long periods of time, as well as the prese... | 01/05/2012 |
| 20120003276 | DERMAL MICRO-ORGANS, METHODS AND APPARATUSES FOR PRODUCING AND USING THE SAME Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and thr... | 01/05/2012 |
| 20120003196 | LONG LASTING DRUG FORMULATIONS The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regula... | 01/05/2012 |
| 20120003194 | IN VITRO MICRO-ORGANS, AND USES RELATED THERETO Micro-organ cultures which include isolated populations of cells having specific characteristics are described. Salient features of the subject micro-organ cultures include the ability to be maintained in culture for relatively long periods of time, as well as the prese... | 01/05/2012 |
| 20110318316 | CHINESE HAMSTER APOPTOSIS-RELATED GENES Provided is an isolated polypeptide comprising a Cricetulus griseus sequence capable of mediating apoptosis of a cell, the sequence being selected from a FAIM sequence shown as SEQ ID NO: 1; a FADD sequence shown as SEQ ID NO: 2; a PDCD6 sequence shown as SEQ ID ... | 12/29/2011 |
| 20110318355 | MUTANT PROTEINS OF THE F PROTEIN OF PIV-5 AND PIV-2 The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, su... | 12/29/2011 |
| 20110318318 | ANTI-APOPTOTIC FUSION PROTEINS The present invention relates to a fusion protein comprising a protein transduction domain capable of introducing the fusion protein into a mammalian cell and an anti-apoptotic protein comprising the amino acid of the sequence of SEQ ID NO:1 or an anti-apoptotically act... | 12/29/2011 |
| 20110318389 | HUMAN PANCREATIC BETA CELL LINES FOR DIAGNOSTIC OF DIABETES The present invention relates to a method for preparing commercial scale quantities of human functional Betacells and to the establishment of cell lines. It also relates to a method of diagnosis using Beta cell tumors or cells derived thereof. The method comprises sub-t... | 12/29/2011 |
| 20110318317 | CHINESE HAMSTER APOPTOSIS-RELATED GENES Provided is an isolated polypeptide comprising a Cricetulus griseus sequence capable of mediating apoptosis of a cell, the sequence being selected from a FAIM sequence shown as SEQ ID NO: 1; a FADD sequence shown as SEQ ID NO: 2; a PDCD6 sequence shown as SEQ ID ... | 12/29/2011 |
